Patents by Inventor Scott Mitchell

Scott Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12263163
    Abstract: The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: April 1, 2025
    Assignee: Kronos Bio, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Jin-Ming Xiong, Jianjun Xu, Sundaramoorthi Swaminathan, Zhongdong Zhao
  • Publication number: 20250101319
    Abstract: This invention relates to a process for chemically treating a carbon-containing feedstock (e.g., a polymer-based feedstock), comprising contacting (e.g., by a hydrocracking reaction) the carbon-containing feedstock and a hydrogen stream in the presence of at least one hydrocracking catalyst to produce an alkane-containing product stream. The hydrocracking catalyst comprises at least one transition metal or transition metal sulfide supported on an oxide-containing support. This invention also relates to an alkane-containing mixture obtained by the process described herein and a system/apparatus for carrying out the process described herein.
    Type: Application
    Filed: September 26, 2024
    Publication date: March 27, 2025
    Inventors: Vibin Vargheese, Nicholas Wang, Matthew Feeney, Ishant Khurana, Jan Kalfus, Scott Mitchell, Richard Opfer
  • Patent number: 12258346
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: December 18, 2023
    Date of Patent: March 25, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A Codelli, John H. Conway, Jennifer L Cosman Ellis, Rao V. Kalla, Zachary A Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Patent number: 12252943
    Abstract: An improved debris catcher and choke system for receiving a pressurized fluid stream from wellbore operations where a controller can selectively place a plurality of debris catchers in debris catching or flushing modes, and the cleaned fluids from one of the debris catchers can be used to flush one of the other debris catchers. One or more embodiments relate to systems and methods for utilizing debris catchers and choke valves.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: March 18, 2025
    Assignee: TETRA Technologies, Inc.
    Inventors: Virgilio Garcia Soule, James Matthew Watson, Brandon Scott Mitchell, Travis Martin Bahrt
  • Publication number: 20250074845
    Abstract: A heterogeneous catalyst composition including a metal and boron catalyst with boron dispersed in a molten matrix, where the molten matrix includes a eutectic mixture of alkali metal or alkaline earth metal salts or hydroxides. A process for preparing a heterogeneous catalyst composition, including combining a mixture of alkali metal or alkaline earth metal salts or hydroxides to form a matrix including a eutectic mixture, adding, to the matrix, a boron precursor and at least one metal catalyst precursor to form a catalyst precursor mixture, and heating the catalyst precursor mixture to a temperature of from 390° C. to 750° C. to form the heterogeneous catalyst composition. A process for catalytic oxidative dehydrogenation of hydrocarbons whereby a hydrocarbon-containing feedstock contacts the heterogeneous catalyst composition to generate olefinic compounds.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 6, 2025
    Applicant: Braskem America, Inc.
    Inventors: Ishant Khurana, Graham Gregorich, Matthew Feeney, Scott Mitchell
  • Patent number: 12242545
    Abstract: A document management system can include an artificial intelligence-based document manager that can perform one or more predictive operations based on characteristics of a user, a document, a user account, or historical document activity. For instance, the document management system can apply a machine-learning model to determine how long an expiring agreement document is likely to take to renegotiate and can prompt a user to begin the renegotiation process in advance. The document management system can detect a change to language in a particular clause type and can prompt a user to update other documents that include the clause type to include the change. The document management system can determine a type of a document being worked on and can identify one or more actions that a corresponding user may want to take using a machine-learning model trained on similar documents and similar users.
    Type: Grant
    Filed: September 8, 2023
    Date of Patent: March 4, 2025
    Assignee: Docusign, Inc.
    Inventors: Christina Silva Hamlin, Eric M. Zenz, Jacob Scott Mitchell, William Gerard Wetherell, Sedine Jei San Agustin, Aylin Selcukoglu, Megan Elizabeth Schwarz, David Minoru Hirotsu, Dia A. Abulzahab, Mangesh Prabhakar Bhandarkar, Isaac John Steiner, Saul Adams Aguilar, Michael Wayne Fountain
  • Publication number: 20250059174
    Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: August 8, 2024
    Publication date: February 20, 2025
    Inventors: Jiajun ZHANG, Yuk Ming SIU, Peilin XU, Matthew C. RHODES, Hui CAO, Yat Sun OR, Xuri GAO, Wei LI, Xuechao XING, Scott MITCHELL
  • Patent number: 12229116
    Abstract: The present system and method is directed to a process to facilitate trusted sources of information in an enterprise. The present system and method positions data governance to move away from the element level and focus on the data asset (i.e. repository, interface, subject) level. When data persons are having any issue with their data asset, whether it is a conflicting data asset, interface issues, competing data asset, new data asset build, data subject issue, or the like, a certifier may operate to assess the asset based on our well defined metrics, determine the health through the data asset scoring process, recommend asset services, and provide those services to the data owner who is ultimately responsible for implementing them to improve the data and the data processes.
    Type: Grant
    Filed: August 21, 2023
    Date of Patent: February 18, 2025
    Assignee: HARTFORD FIRE INSURANCE COMPANY
    Inventors: Scott Mitchell Mackenthun, James A. Madison
  • Publication number: 20250042898
    Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: July 24, 2024
    Publication date: February 6, 2025
    Inventors: Yuk Ming SIU, Jiajun ZHANG, Matthew C. RHODES, Peilin XU, Hui CAO, Scott MITCHELL, Yat Sun OR
  • Publication number: 20250045515
    Abstract: Systems and methods are disclosed herein for generating and modifying a workflow comprising a series of webpages based on an online document. A document management system accesses an online document selected by a user and classifies each field of the online document into one of a set of categories. For each category, the system generates a form webpage comprising questions corresponding to each field classified as the category and combines the generated webpages to create a workflow. The system may modify the workflow by generating and adding one or more additional form webpages based on one or more answers provided by an entity completing the webform page. In response to the entity completing the modified generated workflow, the system generates a completed document based on the online document and the answers provided by the entity.
    Type: Application
    Filed: October 25, 2024
    Publication date: February 6, 2025
    Inventors: Gustavo Both Bitdinger, Mangesh Prabhakar Bhandarkar, Nipun Dureja, Vasudevan Sampath, Robert Sherwin, Duane Robert Wald, Mark Spencer Seabourne, Claire Marie Small, David Minoru Hirotsu, Dia A Abulzahab, Li Xu, Brent Weston Robinett, Jerome Levadoux, Ellis David Berner, Jun Gao, Andrew James Ashlock, Jacob Scott Mitchell
  • Publication number: 20250027094
    Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Application
    Filed: October 4, 2024
    Publication date: January 23, 2025
    Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark A. Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay H. Russell, Keith A. Canada
  • Publication number: 20250019323
    Abstract: A heterogeneous catalyst composition may include a metal catalyst supported on a porous mixed metal oxide support. A process for catalytic oxidative dehydrogenation of hydrocarbons may include contacting, in a reactor system, a hydrocarbon-containing feedstock with the heterogeneous catalyst composition to generate olefinic compounds. A process for preparing a heterogeneous catalyst composition may include combining a porous mixed metal oxide support with at least one metal catalyst precursor to form a catalyst precursor mixture, wherein the at least one metal catalyst precursor comprises at least one metal compound selected from the group consisting of transition metal compounds, rare-earth metal compounds, or a mixture thereof, and heating the catalyst precursor mixture to a temperature of about 390° C. to about 750° C. to form a heterogeneous catalyst composition.
    Type: Application
    Filed: June 21, 2024
    Publication date: January 16, 2025
    Applicant: Braskem America, Inc.
    Inventors: Ishant Khurana, Graham Gregorich, Scott Mitchell
  • Patent number: 12141413
    Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for evaluating interactions with a user interface are disclosed. In one aspect, a method includes identifying a set of mutation events specifying changes to the structure of a user interface that occurred during the user session, and generating user interface states specifying different structures of the user interface throughout the given user session. Based at least in part on the user interface states, playback data that present visual changes of the user interface corresponding to the set of mutation events that occurred during the user session are generated. Session activity data describing user interactions that occurred during the user session are also generated. At least a portion of the playback data and the session activity data are output to a requesting device.
    Type: Grant
    Filed: May 15, 2023
    Date of Patent: November 12, 2024
    Assignee: FullStory, Inc.
    Inventors: Joel Grayson Webber, Stephanie Jill Brubaker, Hollis Bruce Johnson, Jr., Ian Thomas Rose, Scott Mitchell Voigt, Jaime Michael Yap, Joshua Calvin Teague
  • Publication number: 20240368096
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: February 21, 2024
    Publication date: November 7, 2024
    Inventors: Samuel BARTLETT, Joseph D. PANARESE, Sourav GHORAI, Nathaniel Thomas KENTON, Sean RAFFERTY, Jonathan THIELMAN, Peilin XU, Bin WANG, William CASSELS, Scott MITCHELL, Yat Sun OR
  • Publication number: 20240368174
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 5, 2024
    Publication date: November 7, 2024
    Inventors: Adam SZYMANIAK, Robert LEON, Kevin McGRATH, Xiben LI, Tyler J. MANN, Jianming YU, In Jong KIM, Scott MITCHELL, Yat Sun OR
  • Publication number: 20240362652
    Abstract: According to some embodiments, an enterprise proprietary data store contains a set of electronic data records, each electronic data record having with proprietary data and an associated governance structure. A compliance computer platform may receive the proprietary data and associated governance structure from the enterprise proprietary data store and define enterprise-wide decision accountabilities for the proprietary data based on the governance structure. The compliance computer platform may also define privacy objectives for the proprietary data based on the governance structure along with specific machine-level controls to test and confirm compliance with the governance structure.
    Type: Application
    Filed: July 8, 2024
    Publication date: October 31, 2024
    Inventors: Michael R. Gorman, Scott Mitchell Mackenthun, James A. Madison, Daniel L O'Connell
  • Publication number: 20240327334
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 20, 2023
    Publication date: October 3, 2024
    Inventors: Xuri GAO, Bin WANG, Hui CAO, Jiajun ZHANG, Yuk Ming SIU, Jiang LONG, Wei LI, Matthew C. RHODES, Xuechao XING, Jianming YU, Scott MITCHELL, Yat Sun OR
  • Publication number: 20240325409
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: February 26, 2024
    Publication date: October 3, 2024
    Inventors: Sean RAFFERTY, Sourav GHORAI, Nathaniel Thomas KENTON, Peilin XU, Samuel BARTLETT, Scott MITCHELL, Joseph D. PANARESE, Yat Sun OR
  • Publication number: 20240287391
    Abstract: A process for the cracking of a carbon-containing feedstock to produce olefins, the process includes contacting, in a reactor system, the carbon-containing feedstock with a molten salt matrix consisting of a eutectic mixture of alkali metal carbonates, alkaline earth metal carbonates, or a mixture of any two or more thereof, to generate an olefin-containing product stream; and collecting an olefin from the olefin-containing product stream; wherein: the process is conducted in the absence of oxygen, and in the absence of a catalyst comprising a transition metal, a transition metal oxide, a rare-earth metal, a rare earth metal oxide, or a combination of any two or more thereof.
    Type: Application
    Filed: February 5, 2024
    Publication date: August 29, 2024
    Applicant: Braskem America, Inc.
    Inventors: Samuel L. Leung, Nicholas Wang, Katherine McCullough, Goutham Kothamreddy, Charles Ambrass, Matthew Feeney, Jan Kalfus, Scott Mitchell
  • Publication number: 20240287061
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: December 18, 2023
    Publication date: August 29, 2024
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman Ellis, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki